Influence of Bacterial Superantigen TSST-1 Against the Anti-Proliferative Efficacy of Immunosuppressive Drugs and Interleukin 2 Production in Peripheral Blood Mononuclear Cells of Hemodialysis Patients and Healthy Subjects

REFERENCES

• M. Boratynska, M. Banasik, D. Patrzalek, and M. Klinger. (2006). Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. Ann. Transplant. 11 (2):51–56.
   PubMedGoogle Scholar
• H. Yang. (2006). Maintenance immunosuppression regimens: Conversion, minimization, withdrawal, and avoidance. Am. J. Kidney Dis. 47 (4 Suppl 2):S37–51.
   PubMedGoogle Scholar
• T. Hirano, K. Oka, H. Takeuchi, E. Sakurai, N. Matsuno, T. Tamaki, and M. Kozaki. (1994). Clinical significance of glucocorticoid pharmacodynamics assessed by anti-lymphocyte action in kidney transplantation: Marked difference between prednisolone and methylprednisolone. Transplantation 57:1341–1348.
   PubMed Web of Science ®Google Scholar
• T. Hirano, K. Oka, H. Takeuchi, K. Kozaki, N. Matsuno, T. Nagao, M. Kozaki, M. Ichikawa, M. Yoshida, Y. Umezawa, M. Hirata, T. Oh-i, and M. Koga. (1997). Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis and psoriasis: Possible implications for individual therapeutic efficacy. Clin. Pharmacol. Ther. 62:652–664.
   PubMedGoogle Scholar
• T. Hirano. (2007). Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine (review). Int. Immunopharmacol. 7:3–22.
   PubMed Web of Science ®Google Scholar
• C.J. Corrigan, J.K. Bungre, B. Assoufi, A.E. Cooper, H. Seddon, and A.B. Kay. (1996). Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. Eur. Respir. J. 9 (10):2077–2086.
   PubMedGoogle Scholar
• H. Takeuchi, T. Hirano, K. Oka, K. Mizumoto, T. Akashi, M. Uchiyama, T. Degawa, K. Kozaki, N. Matsuno, T. Nagoa, M. Kozaki, and E. Sakurai. (1998). Lymphocyte-sensitivities to cyclosporine and tacrolimus in chronic renal failure patients and their significance on renal transplantation. Transplant. Proc. 30:36–39.
   PubMedGoogle Scholar
• T. Hirano, T. Akashi, T. Keira, K. Oka, N. Ihoya, and M. Yoshida. (2000). Clinical impact of cyclosporine cellular-pharmacodynamics in minimal change nephrotic syndrome. Clin. Pharmacol. Ther. 68:532–540.
   PubMedGoogle Scholar
• T. Hirano, K. Oka, Y. Umezawa, M. Hirata, T. Oh-I, and M. Koga. (1998). Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine-efficacy in psoriasis. Clin. Pharmacol. Ther. 63:465–470.
   PubMedGoogle Scholar
• B.W. Kirkham, M.M. Corkill, S.C. Davison, and G.S. Panayi. (1991). Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J. Rheumatol. 18:821–825.
   PubMed Web of Science ®Google Scholar
• T. Hirano, T. Akashi, T. Kido, K. Oka, T. Shiratori, and M. Miyaoka. (2002). Immunosuppressant pharmacodynamics on peripheral-blood mononuclear cells from patients with ulcerative colitis. Int. Immunopharmacol. 2:1055–1063.
   PubMedGoogle Scholar
• J.E. Rasmussen. (2000). The relationship between infection with group A beta hemolytic streptococci and the development of psoriasis. Pediatr. Infect. Dis. J. 19:153–154.
   PubMedGoogle Scholar
• P.J Hauk, Q.A. Hamid, G.P. Chrousos, and D.M. Leung. (2000). Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J. Allergy Clin. Immunol. 105:782–787.
   PubMedGoogle Scholar
• P.T. D'Cunha, D.S. Davenport, and K.A. Fisher. (2003). Successful treatment of Staphylococcus aureus bacterial endocarditis in a renal transplant recipient. Transpl. Infect. Dis. 5 (3):144–146.
   PubMedGoogle Scholar
• S. Horn, H. Holzer, and J.H. Horina. (1996). Spontaneous bacterial peritonitis in a patient with nephrogenic ascites during an episode of acute renal transplant rejection. Am. J. Kidney Dis. 27 (3):441–443.
   PubMedGoogle Scholar
• H. Fukushima, T. Hirano, and K. Oka. (2007). Staphylococcus aureus superantigens decreases FKBP51mRNA expression and cell response to suppressive efficacy of glucocorticoid in human peripheral blood mononuclear: Possible implication of MAPK pathways. Eur. J. Pharmacol. 570 (1–3):222–228.
   PubMedGoogle Scholar
• K. Arai, T. Uchiyama, Y. Okubo, R. Tsuboi, K. Oka, and T. Hirano. (2007). Comparative study of the effects of betamethasone butyrate propionate, vitamin D3 derivatives, and cyclosporine on human lymphocyte-proliferation stimulated with a hemolytic streptococci derived superantigen. Eur. J. Pharmacol. 571 (2–3):222–230.
   PubMedGoogle Scholar
• O. Konno, T. Hirano, K. Katsuyama, K. Oka, N. Matsuno, and T. Nagao. (2007). Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with chronic renal failure on hemodialysis treatment. Transplant. Immunol. 17:187–192.
   PubMedGoogle Scholar
• A. Mijiti, N. Matsuno, T. Iwahori, H. Takeuchi, T. Nagao, K. Oka, and T. Hirano. (2006). Increased sensitivities of peripheral-blood mononuclear cells to immunosuppressive drugs in cirrhosis patients awaiting liver transplantation. Cell Transplantation 15:885–891.
   PubMedGoogle Scholar
• Haycock, K.A.; Roth, R.; Gagnon, J. Statview, Berkeley, CA, Abacus Concepts, 1994.
   Google Scholar
• P. Stenvinkel, M. Ketteler, R.J. Johnson, M. Riella, K. Wong, A.R. Qureshi, J. Axelsson, R. Pecoits-Filho, P. Gao, J. Barany, B. Lindholm, T. Jagestrand, O. Heimburger, C. Holmes, M. Schalling, and L. Nordfors. (2005). IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—The good, the bad, and the ugly. Kidney Int. 67 (4):1216–1233.
   PubMedGoogle Scholar
• M. Girndt, C. Ulrich, H. Kaul, U. Sester, M. Sester, and H. Kohler. (2003). Uremia-associated immune defect: the IL-10-CRP axis. Kidney Int. Suppl (84):S76–79.
   Google Scholar
• T. Hirano, K. Oka, and T. Tamaki. (1995). Gramicidin as a potent immunosuppressant for organ transplantation: Suppression of human lymphocyte blastogenesis in vitro and prolongation of heart allograft survival in the rat. J. Pharmacol. Exp. Ther. 273:223–229.
   PubMedGoogle Scholar
• G. Wiederrecht, E. Lam, S. Hung, M. Martin, and N. Sigal. (1993). The mechanism of action of FK-506 and cyclosporin A. Ann. N.Y. Acad. Sci. 696:9–19.
   PubMed Web of Science ®Google Scholar
• T. Uchiyama, T. Tadakuma, K. Imanishi, M. Araake, S. Saito, X.J. Yan, H. Fujikawa, H. Igarashi, and N. Yomaura. (1989). Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules. J. Immunol. 143:3175–3182.
   Google Scholar
• L.B. Li, E. Goleva, C.F. Hall, L.S. Ou, and D.Y. Leung. (2004). Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase / extracellular signal-regulated kinase (MEK-ERK) pathway. J. Allergy Clin. Immunol. 114:1059–1069.
   PubMed Web of Science ®Google Scholar
• C.E. Edmead, Y.I. Patel, A. Wilson, G. Boulougouris, N.D. Hall, S.G. Ward, and et al (1996). Induction of activator protein (AP)-1 and nuclear factor-kappaB by CD28 stimulation involves both phosphatidylinositol 3-kinase and acidic sphingomyelinase signals. J. Immunol. 157:3290–3297.
   PubMedGoogle Scholar
• T. Koike, H. Yamagishi, Y. Hatanaka, A. Fukushima, J.W. Chang, Y. Xia, M. Fields, P. Chandler, M. Iwashima, and P. Chandler. (2003). Iwashima MA novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation. J. Biol. Chem. 278:15685–15692.
   PubMed Web of Science ®Google Scholar
• F.H. Bender, J. Bernardini, and B. Piraino. (2006). Prevention of infectious complications in peritoneal dialysis: Best demonstrated practices. Kidney Int. Suppl (103):S44–54.
   Google Scholar
• J. Kluytmans, A. van Belkum, and H. Verbrugh. (1997). Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10:505–520.
   PubMed Web of Science ®Google Scholar